First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including...
Read more: First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy






